Apeloa Pharmaceutical Co.,Ltd
000739.SZ · SHZ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 10.54B | 2.47B | 1.01B | 989.17M | 0.85 |
| 2023 FY | 11.47B | 2.85B | 1.22B | 1.06B | 0.90 |
| 2024 FY | 12.02B | 2.80B | 1.21B | 1.03B | 0.89 |
| 2025 FY | 9.76B | 2.37B | 878.92M | 890.68M | 0.77 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 12.02B | 6.50B | 3.55B | 828.25M | 5.51B |
| 2023 FY | 12.77B | 6.54B | 3.58B | 830.98M | 6.22B |
| 2024 FY | 12.73B | 5.98B | 3.66B | 897.86M | 6.74B |
| 2025 FY | 12.32B | 5.97B | 3.79B | 1.51B | 6.34B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 1.33B | -509.11M | 817.00M | -335.88M | 582.76M |
| 2023 FY | 1.03B | -630.47M | 400.90M | -383.02M | 80.57M |
| 2024 FY | 1.21B | -460.75M | 748.01M | -401.63M | 266.96M |
| 2025 FY | 1.23B | -386.21M | 844.46M | -812.46M | 124.81M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 25.19B | 22.46B | — | — | — |
| 2023 FY | 18.00B | 15.25B | — | — | — |
| 2024 FY | 18.84B | 16.07B | — | — | — |
| 2025 FY | 18.76B | 16.49B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 2.71B | 716.57M | 361.81M | 314.50M | 0.27 |
| 2025 Q3 | 2.32B | 541.78M | 155.09M | 137.22M | 0.12 |
| 2025 Q4 | 2.02B | 588.97M | 135.67M | 190.41M | 0.17 |
| 2026 Q1 | 2.45B | 717.19M | 318.88M | 249.02M | 0.22 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 12.48B | 5.73B | 3.57B | 1.18B | 6.75B |
| 2025 Q3 | 12.10B | 5.61B | 3.53B | 2.98B | 6.49B |
| 2025 Q4 | 12.32B | 5.97B | 3.79B | 1.51B | 6.34B |
| 2026 Q1 | 12.25B | 5.68B | 3.63B | 2.97B | 6.56B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 422.17M | -39.93M | 382.24M | -421.31M | 199.72M |
| 2025 Q3 | 366.84M | -53.73M | 313.11M | — | -41.91M |
| 2025 Q4 | 446.18M | -166.73M | 279.45M | -812.46M | 254.59M |
| 2026 Q1 | 124.97M | -109.43M | 15.54M | -8.96M | -151.85M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 16.21B | 13.82B | — | — | — |
| 2025 Q3 | 18.81B | 18.26B | — | — | — |
| 2025 Q4 | 18.66B | 16.39B | — | — | — |
| 2026 Q1 | 20.07B | 19.41B | — | — | — |